Konstantinos Xynos - Dec 1, 2022 Form 4 Insider Report for Replimune Group, Inc. (REPL)

Role
Chief Medical Officer
Signature
/s/ Jean Franchi, attorney-in-fact
Stock symbol
REPL
Transactions as of
Dec 1, 2022
Transactions value $
$0
Form type
4
Date filed
12/5/2022, 07:01 PM
Next filing
Apr 4, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REPL Common Stock Award $0 +17.5K +32.83% $0.00 70.8K Dec 1, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REPL Employee Stock Option (right to buy) Award $0 +26.3K $0.00 26.3K Dec 1, 2022 Common Stock 26.3K $19.98 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on November 15, 2023 and the remainder will vest in three approximately equal annual installments thereafter until November 15, 2026, subject to the Reporting Person's continuous service to the Issuer.
F2 25% of the shares underlying this stock option vest on December 1, 2023, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.